Capital Group Private Client Services, Inc. Bei Gene, Ltd. Transaction History
Capital Group Private Client Services, Inc.
- $9.55 Billion
- Q1 2025
A detailed history of Capital Group Private Client Services, Inc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Capital Group Private Client Services, Inc. holds 152,156 shares of BGNE stock, worth $34.5 Million. This represents 0.36% of its overall portfolio holdings.
Number of Shares
152,156
Previous 159,297
4.48%
Holding current value
$34.5 Million
Previous $29.4 Million
17.24%
% of portfolio
0.36%
Previous 0.29%
Shares
15 transactions
Others Institutions Holding BGNE
# of Institutions
291Shares Held
40.1MCall Options Held
111KPut Options Held
114K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion23.78% of portfolio
-
Capital International Investors Los Angeles, CA5.09MShares$1.15 Billion0.24% of portfolio
-
Primecap Management CO Pasadena, CA5.06MShares$1.15 Billion0.97% of portfolio
-
Baillie Gifford & CO3.63MShares$823 Million0.74% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.71MShares$615 Million0.09% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...